Spencer T. Evans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Spencer T. Evans has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Kurt Q. Lu
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, USA
6 shared publications - Dan Xu
Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
2 shared publications - Dauren Biyashev
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, USA
2 shared publications - Madison Ernst
University of Minnesota Medical School Minneapolis Minnesota USA
2 shared publications - Michael Demczuk
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, USA
2 shared publications - Nathan C. Gianneschi
Department of Materials Science and Engineering, Northwestern University, Evanston, USA
2 shared publications
Latest Publications
- Open Access
- 6 December 2024
- Published by Springer Nature in npj Regenerative Medicine
- Vol. 9 (1) , 1-11
Attenuation of skin injury by a MARCO targeting PLGA nanoparticle
Cutaneous exposure to the DNA alkylating class of chemotherapeutic agents including nitrogen mustard (NM) leads to both skin injury and systemic inflammation. Circulating myeloid subsets recruited to the skin act to further exacerbate local tissue damage while interfering with the wound healing process. We demonstrate herein that intravenous delivery of poly(lactic-co-glycolic acid) immune-modifying nanoparticles (PLGA-IMPs) shortly after NM exposure restricts accumulation of macrophages and inflammatory monocytes at the injury site, resulting in attenuated skin pathology. Furthermore, PLGA-IMPs induce an early influx and local enrichment of Foxp3+ regulatory T cells (Treg) in the skin lesions critical for the suppression of myeloid cell-pro-inflammatory responses via induction of IL-10 and TGF-β in the cutaneous milieu. Functional depletion of CD4+ Tregs ablates the efficacy of PLGA-IMPs accompanied by a loss of local accumulation of anti-inflammatory cytokines essential for wound healing. Thus, in severe skin trauma, PLGA-IMPs may have therapeutic potential via modulation of inflammatory myeloid cells and regulatory T lymphocytes.
- 6 December 2024
- Published by Springer Nature in npj Regenerative Medicine
- Vol. 9 (1) , 1-11
Open AccessAttenuation of skin injury by a MARCO targeting PLGA nanoparticle
Cutaneous exposure to the DNA alkylating class of chemotherapeutic agents including nitrogen mustard (NM) leads to both skin injury and systemic inflammation. Circulating myeloid subsets recruited to the skin act to further exacerbate local tissue damage while interfering with the wound healing process. We demonstrate herein that intravenous delivery of poly(lactic-co-glycolic acid) immune-modifying nanoparticles (PLGA-IMPs) shortly after NM exposure restricts accumulation of macrophages and inflammatory monocytes at the injury site, resulting in attenuated skin pathology. Furthermore, PLGA-IMPs induce an early influx and local enrichment of Foxp3+ regulatory T cells (Treg) in the skin lesions critical for the suppression of myeloid cell-pro-inflammatory responses via induction of IL-10 and TGF-β in the cutaneous milieu. Functional depletion of CD4+ Tregs ablates the efficacy of PLGA-IMPs accompanied by a loss of local accumulation of anti-inflammatory cytokines essential for wound healing. Thus, in severe skin trauma, PLGA-IMPs may have therapeutic potential via modulation of inflammatory myeloid cells and regulatory T lymphocytes.
- 11 January 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (7) , 1491-1504.e10
Profibrotic Subsets of SPP1+ Macrophages and POSTN+ Fibroblasts Contribute to Fibrotic Scarring in Acne Keloidalis
- 11 January 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (7) , 1491-1504.e10
Profibrotic Subsets of SPP1+ Macrophages and POSTN+ Fibroblasts Contribute to Fibrotic Scarring in Acne Keloidalis
- Open Access
- 2 November 2023
- Published by Springer Nature in npj Regenerative Medicine
- Vol. 8 (1) , 1-14
Topical application of synthetic melanin promotes tissue repair
In acute skin injury, healing is impaired by the excessive release of reactive oxygen species (ROS). Melanin, an efficient scavenger of radical species in the skin, performs a key role in ROS scavenging in response to UV radiation and is upregulated in response to toxic insult. In a chemical injury model in mice, we demonstrate that the topical application of synthetic melanin particles (SMPs) significantly decreases edema, reduces eschar detachment time, and increases the rate of wound area reduction compared to vehicle controls. Furthermore, these results were replicated in a UV-injury model. Immune array analysis shows downregulated gene expression in apoptotic and inflammatory signaling pathways consistent with histological reduction in apoptosis. Mechanistically, synthetic melanin intervention increases superoxide dismutase (SOD) activity, decreases Mmp9 expression, and suppresses ERK1/2 phosphorylation. Furthermore, we observed that the application of SMPs caused increased populations of anti-inflammatory immune cells to accumulate in the skin, mirroring their decrease from splenic populations. To enhance antioxidant capacity, an engineered biomimetic High Surface Area SMP was deployed, exhibiting increased wound healing efficiency. Finally, in human skin explants, SMP intervention significantly decreased the damage caused by chemical injury. Therefore, SMPs are promising and effective candidates as topical therapies for accelerated wound healing, including via pathways validated in human skin.
- 2 November 2023
- Published by Springer Nature in npj Regenerative Medicine
- Vol. 8 (1) , 1-14
Open AccessTopical application of synthetic melanin promotes tissue repair
In acute skin injury, healing is impaired by the excessive release of reactive oxygen species (ROS). Melanin, an efficient scavenger of radical species in the skin, performs a key role in ROS scavenging in response to UV radiation and is upregulated in response to toxic insult. In a chemical injury model in mice, we demonstrate that the topical application of synthetic melanin particles (SMPs) significantly decreases edema, reduces eschar detachment time, and increases the rate of wound area reduction compared to vehicle controls. Furthermore, these results were replicated in a UV-injury model. Immune array analysis shows downregulated gene expression in apoptotic and inflammatory signaling pathways consistent with histological reduction in apoptosis. Mechanistically, synthetic melanin intervention increases superoxide dismutase (SOD) activity, decreases Mmp9 expression, and suppresses ERK1/2 phosphorylation. Furthermore, we observed that the application of SMPs caused increased populations of anti-inflammatory immune cells to accumulate in the skin, mirroring their decrease from splenic populations. To enhance antioxidant capacity, an engineered biomimetic High Surface Area SMP was deployed, exhibiting increased wound healing efficiency. Finally, in human skin explants, SMP intervention significantly decreased the damage caused by chemical injury. Therefore, SMPs are promising and effective candidates as topical therapies for accelerated wound healing, including via pathways validated in human skin.
- Open Access
- 24 January 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (2)
Vitamin D3 and deconvoluting a rash
BACKGROUND: Adverse drug reactions are unpredictable immunologic events presenting frequent challenges to clinical management. Systemically administered cholecalciferol (vitamin D 3 ) has immunomodulatory properties. In this randomized, double-blinded, placebo-controlled interventional trial of healthy human adults, we investigated the clinical and molecular immunomodulatory effects of a single high dose of oral vitamin D 3 on an experimentally induced chemical rash. METHODS: Skin inflammation was induced with topical nitrogen mustard (NM) in 28 participants. Participant-specific inflammatory responses to NM alone were characterized using clinical measures, serum studies, and skin tissue analysis over the next week. All participants underwent repeat NM exposure to the opposite arm and then received placebo or 200,000 IU cholecalciferol intervention. The complete rash reaction was followed by multi-omic analysis, clinical measures, and serum studies over 6 weeks. RESULTS: Cholecalciferol mitigated acute inflammation in all participants and achieved 6 weeks of durable responses. Integrative analysis of skin and blood identified an unexpected divergence in response severity to NM, corroborated by systemic neutrophilia and significant histopathologic and clinical differences. Multi-omic and pathway analyses revealed a 3-biomarker signature (CCL20, CCL2, CXCL8) unique to exaggerated responders that is suppressed by cholecalciferol and implicates IL-17 signaling involvement. CONCLUSION: High-dose systemic cholecalciferol may be an effective treatment for severe reactions to topical chemotherapy. Our findings have broad implications for cholecalciferol as an antiinflammatory intervention against the development of exaggerated immune responses. TRIAL REGISTRATION: clinicaltrials.gov (NCT02968446). FUNDING: NIH and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; grants U01AR064144, U01AR071168, P30 AR075049, U54 AR079795, and P30 AR039750 (CWRU)).
- 24 January 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (2)
Open AccessVitamin D3 and deconvoluting a rash
BACKGROUND: Adverse drug reactions are unpredictable immunologic events presenting frequent challenges to clinical management. Systemically administered cholecalciferol (vitamin D 3 ) has immunomodulatory properties. In this randomized, double-blinded, placebo-controlled interventional trial of healthy human adults, we investigated the clinical and molecular immunomodulatory effects of a single high dose of oral vitamin D 3 on an experimentally induced chemical rash. METHODS: Skin inflammation was induced with topical nitrogen mustard (NM) in 28 participants. Participant-specific inflammatory responses to NM alone were characterized using clinical measures, serum studies, and skin tissue analysis over the next week. All participants underwent repeat NM exposure to the opposite arm and then received placebo or 200,000 IU cholecalciferol intervention. The complete rash reaction was followed by multi-omic analysis, clinical measures, and serum studies over 6 weeks. RESULTS: Cholecalciferol mitigated acute inflammation in all participants and achieved 6 weeks of durable responses. Integrative analysis of skin and blood identified an unexpected divergence in response severity to NM, corroborated by systemic neutrophilia and significant histopathologic and clinical differences. Multi-omic and pathway analyses revealed a 3-biomarker signature (CCL20, CCL2, CXCL8) unique to exaggerated responders that is suppressed by cholecalciferol and implicates IL-17 signaling involvement. CONCLUSION: High-dose systemic cholecalciferol may be an effective treatment for severe reactions to topical chemotherapy. Our findings have broad implications for cholecalciferol as an antiinflammatory intervention against the development of exaggerated immune responses. TRIAL REGISTRATION: clinicaltrials.gov (NCT02968446). FUNDING: NIH and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; grants U01AR064144, U01AR071168, P30 AR075049, U54 AR079795, and P30 AR039750 (CWRU)).
- 31 August 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (3) , 517-520.e12
Skin Tape Strip Proteomics in Mycosis Fungoides Identifies Tumor-Associated Biomarkers
- 31 August 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (3) , 517-520.e12
Skin Tape Strip Proteomics in Mycosis Fungoides Identifies Tumor-Associated Biomarkers
- 5 May 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 3125-3127
In Vitro and Ex Vivo Investigation of Intralesional Sodium Thiosulfate as a Reversal Agent for Calcium Hydroxylapatite Soft Tissue Filler
- 5 May 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 3125-3127
In Vitro and Ex Vivo Investigation of Intralesional Sodium Thiosulfate as a Reversal Agent for Calcium Hydroxylapatite Soft Tissue Filler